# Atrial fibrillation, bleeding and high blood pressure on BTK inhibitors: assessment, monitoring and management

Source: https://onco.cc/protocols/atrial-fibrillation-and-bleeding-on-btk-inhibitors/  
OnCo record `atrial-fibrillation-and-bleeding-on-btk-inhibitors` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BTK inhibitors such as ibrutinib can cause an irregular heartbeat (atrial fibrillation), bleeding and bruising, and high blood pressure. Your team checks your pulse and blood pressure and reviews any blood thinners. The medicine may be paused around an operation or dental work. Report straight away a fast or irregular heartbeat, feeling faint, chest discomfort, or bleeding you cannot control.

## Summary

Before a BTK inhibitor, take a cardiovascular history and record blood pressure and an ECG (both consensus statements; the ibrutinib label says to evaluate cardiac history and function at baseline), with an echocardiogram for people at high cardiovascular risk (ESC 2022 Class I, Level C). ESC recommends blood pressure at every visit (Class I, Level B) and a pulse check or ECG rhythm strip at every visit (Class I, Level C), and says home readings weekly for 3 months and then monthly should be considered (Class IIa, Level C).

On the choice of drug the sources differ. ESC 2022 says the data do not yet support different monitoring strategies for ibrutinib and acalabrutinib. Two consensus statements, both funded by AstraZeneca, the maker of acalabrutinib, prefer acalabrutinib or zanubrutinib to ibrutinib in people with established cardiovascular disease and advise against BTK inhibitors, especially ibrutinib, after ventricular arrhythmia or cardiac arrest. In the ELEVATE-RR trial atrial fibrillation of any grade occurred in 16 per cent on ibrutinib and 9 per cent on acalabrutinib. The ibrutinib label warns of fatal arrhythmias, cardiac failure and sudden death.

ESC says that neither atrial fibrillation nor the risk of it is a contraindication to cancer treatment. It says rate control, preferably with a beta-blocker, should be considered for well-tolerated atrial fibrillation (Class IIa, Level C), with diltiazem and verapamil avoided where possible. Long-term anticoagulation is recommended at a CHA2DS2-VASc score of 2 or more in men or 3 or more in women (ESC Class I, Level C) and should be considered at 1 in men or 2 in women (Class IIa, Level C), weighed against bleeding risk. ESC says a direct oral anticoagulant should be considered in preference to low molecular weight heparin and vitamin K antagonists such as warfarin, in people without a high bleeding risk, significant drug interactions or severe renal dysfunction (Class IIa, Level B). The Australia and New Zealand consensus says to avoid warfarin if possible because most BTK inhibitor trials excluded it (Class IIb, Level C) and to switch to a direct oral anticoagulant, preferably apixaban (Class IIa, Level C). The same consensus says dual antiplatelet therapy should generally be avoided (Class IIb, Level C), and ESC says ibrutinib should be temporarily interrupted in people who need it. All four labels say to consider withholding the drug for 3 to 7 days before and after surgery (the ibrutinib label says at least 3 to 7 days); the Australia and New Zealand consensus sets 3 days for minor and 7 days for major procedures (Class IIa, Level C). Bleeding from low platelets is covered by a separate protocol. This page explains care; the treating team's own protocol and the product's current label come first.

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: ibrutinib atrial fibrillation; BTK inhibitor cardiotoxicity; ibrutinib bleeding; stopping ibrutinib before surgery; anticoagulation on ibrutinib; acalabrutinib heart rhythm; zanubrutinib atrial fibrillation; pirtobrutinib bleeding; ibrutinib and warfarin; BTK inhibitor hypertension
- Tags: protocol; cardio-oncology; side-effect-management

## Connected records

- protocols: [Bleeding precautions at home when platelets are low](https://onco.cc/protocols/bleeding-precautions-when-platelets-are-low/), [Blood thinners around cancer surgery, biopsy and endoscopy: when to stop, whether to bridge, when to restart](https://onco.cc/protocols/antithrombotic-interruption-around-surgery/), [Drug, herbal and food interaction review for anticancer treatment](https://onco.cc/protocols/anticancer-drug-interaction-review/), [Headache on anticancer drugs: assessment, acalabrutinib headache and when it signals something else](https://onco.cc/protocols/headache-on-anticancer-drugs/), [Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment](https://onco.cc/protocols/cardio-oncology-risk-assessment-and-cardiac-surveillance/), [High blood pressure and protein in the urine on VEGF-pathway inhibitors: monitoring, treatment and when to pause the cancer medicine](https://onco.cc/protocols/hypertension-and-proteinuria-on-vegf-pathway-inhibitors/), [Joint pain, muscle pain, cramps and raised creatine kinase on anticancer drugs](https://onco.cc/protocols/joint-and-muscle-pain-on-anticancer-drugs/)
- technologies: [Cardio-oncology](https://onco.cc/technologies/cardio-oncology/)
- pairings: [Caution: ibrutinib in patients with cardiac risk](https://onco.cc/pairings/btki-ibrutinib-cardiac-caution/)
- key papers: [2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)](https://onco.cc/key-papers/paper-lyon-eur-heart-j/)
- fronts: [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- targets: [BTK (Bruton tyrosine kinase)](https://onco.cc/targets/btk/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Ibrutinib](https://onco.cc/drugs/ibrutinib/), [Pirtobrutinib](https://onco.cc/drugs/pirtobrutinib/), [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/)
- institutions: [European Society for Medical Oncology (ESMO)](https://onco.cc/institutions/esmo/)
- terms: [Cardiotoxicity (LVEF decline, cardiomyopathy)](https://onco.cc/terms/cardiotoxicity/)

---
JSON: https://onco.cc/api/v1/entities/atrial-fibrillation-and-bleeding-on-btk-inhibitors.json